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CYSTIC LESIONS OF THE PANCREAS
ABSTRACT
Warshaw, A. L, Compton, C. C., Lewandrowski, K., Cardenosa, G. and Mueller, P. R.
(1990) Cystic tumors of the pancreas. New clinical, radiologic and pathologic observa-
tions in 67 patiems. Annals ofSurgery, 212, 432-445.
Within a 12-year period we treated 67 patients (49 women, 18 men; mean age, 61 years)
with cystic neoplasms of the pancreas, including 18 serous cystic adenomas, 15 benign
mucinous cystic neoplasms, 27 mucinous cystadenocarcinomas, 3 papillary cystic tu-
mors, 2 cystic islet cell tumors, and 2 cases of mucinous ductal ectasia. Mean tumor size
was 6cm (2 to 16cm). In 39% the patients had no symptoms, and in 37% the lesions had
been misdiagnosed as a pseudocyst. Computed tomography was useful for detection, for
distinguishing the microcystic subgroup of serous cystadenoma, and for showing rim
calcification (all 7 cases were malignant) but was not reliable for distinguishing neoplasm
from pseudocyst, serous from mucinous tumors, or benign from malignant. Arteriogra-
phy showed hypervascularity in 4 of 10 serous adenomas, 3 of 11 mucinous carcinomas,
and I of I papillar cystic tumors. Endoscopic pancreatography showed no communication
with the cyst cavity in 37 of37 cases of cystic neoplasms but opacified the ectatic ducts in
2 of 2 cases of mucinous ductal ectasia. Stenosis or obstruction of the pancreatic duct
indicated cancer. The tumor was resected by distal pancreatectomy in 25 patients, by
proximal resection in 29, and by total pancreatectomy in one, with no operative deaths.
Forty-four percent of the tumors were malignant. In 10 cases the tumor was unresectable
because of local extension or distant metastases, and those patients died at a mean of
4 months. Seventy-five percent of those resected for cure are alive without evident
recurrence. Because the epithelial lining ofthe tumor was partially (5% to 98%) absent in
40% to 72% of cases of the major tumor types, and the mucinous component comprised
only about 65% of mucinous cystadenoma lining, misdiagnoses on frozen and even
permanent sections were made. Mitoses and histologic solid growth correlated with
malignancy. Neuroendorine elements were seen in 87% of benign and 47% of malignant
mucinous tumors. It is recommended that the terms macrocystic and microcystic be
abandoned in favor of the histologic designations serous and mucinous. Incomplete
examination of the cyst wall can be misleading, however. It is suggested that mucinous
ductal ectasia be recognized separately from cystic tumors and that all of these
lesions be resected, with the possible exception of asymptomatic confirmed serous
cystadenomas.
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PAPER DISCUSSION
Dr. Warshaw and his colleagues, certainly leading
authorities on the subject of cystic neoplasms of the
pancreas, have once again produced a paper of great
interest. They have succeeded in giving us reliable
guidelines on the diagnosis and treatment of this com-
plex group oftumours in an article which demonstrates
the depth of their experience and knowledge of pancre-
atic surgery.
Cystic tumours of the pancreas are not as common
as pseudocysts but the distinction is vital 1’2. Early
adequate treatment of a malignant cystic neoplasm
gives the patient a reasonable chance of cure whereas
an inadvertent cystenterostomy reduces the prospects
substantially.HPB INTERNATIONAL 73
A previous publication from Warshaw and Rutledge
had focused on the distinction between neoplastic cysts
(benign or malignant) and pseudocysts, based on both
clinical parameters and imaging criteria, and is there-
fore essential reading for all clinicians involved in the
management of patients with pancreatic disease3. Pa-
tients with neoplastic cysts usually have no history of
acute or chronic pancreatitis nor of gallstones, alcohol
abuse or trauma. Serum amylase is likely to be normal
in neoplasia but raised in over half of the patients with
a pancreatic pseudocyst. On imaging neoplastic cysts
are more likely to be irregular or septate and may
contain solid components. The wall is often calcified,
calcification being confined to the cyst wall and not
apparent in other parts ofthe pancreas which would be
more likely in a pseudocyst due to the association with
chronic pancreatitis4. Duct abnormalities characteris-
tic of chronic pancreatitis may also be present in
patients with pseudocysts where ERCP will identify
cyst-duct communication in over 60% of patients.
Such a communication would be exceptional in neo-
plastic cysts.
In this earlier publication Warshaw and Rutledge
suggested that for diagnostic certainty aspiration ofthe
cyst should be performed for amylase estimation and
cytological examination. However, in the more recent
article Dr. Warshaw has veered away from aspiration
because of the risk of seeding of malignant cells in the
needle track. We agree completely with this approach
as we have found needle track seeding to be a real
problem, particularly when biopsy is used for resect-
able malignant liver tumours 5. To confuse the issue
further aspiration of a neoplastic cyst may yield nega-
tive cytology and may even give an elevated amylase
level5’6. We therefore prefer to rely upon those previ-
ously mentioned criteria to make a diagnosis and to
provide a therapeutic strategy but would certainly not
undertake percutaneous cyst aspiration if malignancy
were a possible diagnosis.
We also share the reservations of the authors on the
subject of biopsy of the cyst wall at the time of surgery.
Absence of an epithelial lining must not be used to
confirm the diagnosis of a pseudocyst since the epi-
thelial lining is missing in many cases of cystic neo-
plasm. Frozen and even permanent section may fail to
identify malignancy. If negative intraoperative histol-
ogy is so unreliable, why should we then open a cyst to
take a biopsy instead of resecting it in its entirety ifwe
are doubtful as to its aetiology? A cyst-enterostomy
should never be carried out in a patient where there
may be a possibility that the lesion is neoplastic. The
treatment of choice is resection! This may mean that
rarely (one out of 68 patients in the experience of
Warshaw and colleagues) patients with pseudocysts
will undergo an inadvertent pancreatic resection.
However, this is not such a disaster since resection is
a reasonable treatment for large pseudocysts2, and pre-
ferable to leaving behind a possibly curable tumour or
creating needle track seeding. We do not feel that this
is too radical an approach when Warshaw et al.,
ourselves and others have shown that the mortality
rate for pancreatectomy in the 1990s can be as low as
0_40/o7-o"
Within the group of cystic pancreatic neoplasms is it
possible to distinguish benign from malignant lesions
by preoperative imaging? Warshaw and colleagues
have shown that CT and ultrasound are good tech-
niques for detecting neoplastic cysts but rarely reliable
for the prediction, or exclusion, of malignancy. For
example, multiple small loculations are supposed to
indicate a benign lesion but were found in only 50%
of serous cystadenomas. A central scar with sunburst
calcification is exclusively found in serous cys-
tadenomas but was present in two cases only (11%).
Nevertheless it may occasionally be used to ’confirm’
the diagnosis ofa benign lesion in a surgically high risk
patient. In turn a peripheral rim of calcification on CT
scan may indicate malignancy as all seven tumours in
which it was seen turned out to be malignant. This
should not be confused with pancreatic calcification
seen in patients with pseudocysts secondary to chronic
pancreatitis. Angiography was not found to be a useful
discri-minator, neither was size useful. Both benign
and malignant cysts varied in size from 2 to 16cm and
were unilocular or multilocular.
There are reports in the literature that cystadenocar-
cinomas have an extremely high cure rate. Dr. War-
shaw and colleagues, in this large series of patients,
have a resectability rate of "only" 63% and corre-
sponding overall cure rate of48%. This compares with
our own figure of curative resection for cystadenocar-
cinomas ofapproximately 60%. Although not a "high"
cure rate, 48% is superior to results in selected sub-
groups of resectable periampullary cancer, and is very
much better than the outcome of ductal adenocar-
cinoma of the pancreas. Nowadays when aggressive
surgical resection of solid pancreatic cancer is becom-
ing accepted as a reasonable therapeutic option it
would be a great shame if cystic neoplasms, with their
much better prognosis, were to be left undertreated
with surgical conservativism and scepticism. As
pointed out by Warshaw, we advocate that these
patients should always undergo experienced surgical
exploration with a view to pancreatic resection.74 HPB INTERNATIONAL
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HAS PROPRANOLOL RENDERED SCLEROTHERAPY OBSOLETE
FOR POOR RISK ALCOHOLIC CIRRHOTIC PATIENTS?
ABSTRACT
Ink, 0., Martin, T., Poynard, T., Reville, M., Anciaux, M.-L, Lenoir, C., Marill, J.-L.,
Labadie, H., Masliah, C., Perrin, D., Chaput, J.-C., Vetter, D., Eugene, C., Lebodic, L.,
Licht, H. and Etienne, J.-P. (1992) Does elective sclerotherapy improve the efficacy of
long-term propranolol jbr prevention of recurrent bleeding in patients with severe
cirrhosis? A prospective multicenter, randomized trial. Hepatology; 16:912-919
We conducted a prospective, multicenter, randomized trial to compare the efficacy of
sclerotherapy plus propranolol with that of propranoloi alone in the prevention of
recurrent gastroesophageal bleeding in severely cirrhotic patients. For 2 yr (1987 to 1988)
131 patients (96% ofwhom were alcoholic) with Child-Pugh class B or C cirrhosis (56%
were class B and 44% were class C) were randomly assigned to one of our two treatment
groups after cessation of variceal bleeding, without hernostatic sclerosis, and were
observed for at least 2 yr. Treatment observance was good in 89% of cases; alcohol
withdrawal was observed in 62% of cases. Sclerotherapy was performed weekly with 1%
polidocanol, and variceal obliteration was obtained in 83% ofcases, in a mean number of
four sessions. "lhe cumulative percentages (expressed as mean __+ S.D.) of recurrent
bleeding at 2 yr were 42% ___
6% for propranolol plus sclerotherapy and 59% +_ 6% for
propranolol alone (a nonsignificant difference). Twenty-eight patients from the prop-
ranolol group but only 12 patients from the propranoloi-plus-sclerotherapy group had
recurrent bleeding from esophageal variceal rupture (p < 0.01). The total number of blood
units per patient with recurrent bleeding was slightly but not significantly more important
in the propranolol group (8 __+ 7) than in the propranoloi-plus-sclerotherapy group (5 ___
5;
p--0.09). There were no statistical differences in the cumulative survival rate at 2 yr
(propranolol plus sclerotherapy, 74% __+ 6% and propranolol alone, 64% __+ 6%) or in the
number of patients who died of repeat bleeding (propranolol plus sclerotherapy,
13% __+ 4% and propranolol alone, 17% + 5%). Among the surviving patients, cirrhosis